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Several reports have recently shown that drug-resistant human immunodeficiency virus type 1 (HIV-1) is often isolated from treatment-
naRve patients. We phenotypically analyzed HIV-1 strains isolated from 44 treatment-naRve individuals and found two strains highly resistant
(69- and N310-fold) against nevirapine (NVP). Direct sequencing showed these two isolates had a novel mutation, K238S, in reverse
transcriptase (RT), but did not have any reported NVP resistance-associated mutation.
A 48-h culture in the presence of NVP, however, selected HIV-1 carrying NVP resistance-associated mutations, V106A, V108I, or both,
suggesting that minor viral populations of these two isolates had harbored these mutations. Replication kinetic studies of recombinant HIV-1
clones suggested that K238S conferred a significant resistance against NVP, especially when accompanied with V106A (530-fold) or V108I
(56-fold). Our study identified a novel NVP resistance-associated mutation, K238S, which could be persistently detected by genotypic assay
longer than V106A and V108I during off-treatment period.
D 2004 Elsevier Inc. All rights reserved.
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The emergence of human immunodeficiency virus type 1
(HIV-1) variants resistant to antiretroviral agents is one of
the most common causes for therapeutic failure in infected
individuals. Fortunately, the availability of drug-resistance
testing has substantially improved the ability of clinicians to
deal knowledgeably with drug-resistant HIV-1 variants.
Various guidelines for therapy of HIV-1 infection recom-
mend that each individual therapy should be optimized by
choosing efficient agents based on the results of drug-
resistance testing. Numerous studies have recently reported
that significant proportion of newly diagnosed HIV-10042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: higatana@imcj.acc.go.jp (H. Gatanaga).infection cases are infected with viral strains resistant to at
least one antiretroviral agent, justifying drug-resistance
testing even in treatment-naRve patients (Briones et al.,
2001; Duwe et al., 2001; Grant et al., 2002; Little et al.,
2002; Salomon et al., 2000; Simon et al., 2002). However, it
is important to recognize that the ability to detect resistant
viruses may decrease as a function of time from initial
infection because there is generally a shift to wild type over
time during off-treatment (Devereux et al., 1999; Miller et
al., 2000; Verhofstede et al., 1999). The usefulness of
phenotypic assay could be enhanced if the virus is
propagated in the presence of drug, because such a
condition could propagate resistant viral strains that might
have been outgrown by wild-type viruses in the absence of
drug pressure. In this study, we screened 44 clinical strains
isolated from newly infected individuals by using pheno-
typic assay and identified two highly nevirapine (NVP)-
resistant isolates that could not be detected by genotypic04) 215–224
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genetically closely related and probably originated from a
single patient. Furthermore, we identified a novel NVP
resistance-associated mutation, K238S, in these isolates and
determined its role in viral replication and resistance using
newly generated recombinant HIV-1 clones.Results
NVP-resistant HIV-1 from treatment-naı¨ve patients
From January 2000 through December 2001, a total of 44
patients, who had had clinical evidence of recent HIV-1
infection (seroconversion or increased bands of western
blotting against HIV-1 antigens), visited our clinic and all of
them gave written informed consent to the participation in
this study. To determine the prevalence of drug resistance in
recent HIV-1 infection, susceptibility of HIV-1 isolates
derived from these patients to six antiretroviral agents
including zidovudine (AZT), lamivudine (3TC), stavudine
(d4T), abacavir (ABC), NVP, and efavirenz (EFV) was
examined phenotypically by using MAGIC-5 cells (CCR5
and CD4 expressing HeLa-LTR-h-gal cells) (Hachiya et al.,
2001). As expected, most of such isolates were sensitive to all
tested antiretroviral agents. However, two isolates (4.5%;
isolated from Cases 33 and 23) showed significantly greater
resistance (69-fold and more than 310-fold compared with
NL4-3) to NVP, though their resistance to EFV was not high
(Fig. 1, Table 1).
To delineate the mechanism of the NVP resistance in the
above two isolates, direct sequencing of HIV-1 reverse
transcriptase (RT) gene from plasma samples was performed.
Both plasma-derived sequences did not have any non-
nucleoside RT inhibitor (NNRTI) resistance-associated
mutations listed in resistance table of the International AIDS
Society (Johnson et al., 2003) but had six-amino-acid
substitutions including V35I, R83K, I135T, T200K,
R211K, and K238S, compared with HXBII sequences, and
the plasma-derived sequence in Case 23 had a mixture of
K102 andK102R (Table 2).We postulated that there might be
a minor viral population harboring NNRTI resistance-Fig. 1. Results of drug resistance assay using MAGIC-5 cells in treatment-
naRve individuals. Fold resistances compared with NL4-3 are shown.associated mutations in both plasma samples, which could
not be detected by direct sequencing. To detect such a minor
NVP-resistant viral population, the clinical isolates were
propagated in MAGIC-5 cells in the presence of NVP at
various concentrations and the RT gene of HIV-1 obtained
from a 48-h culture supernatant was analyzed. In the HIV-1
isolated from Case 33, V108I, known as a NVP resistance-
associated mutation, emerged in the presence of NVP (1 AM)
although it could not be detected in direct sequencing of
plasma (Table 2). In the HIV-1 isolated from Case 23,
V106A, andV108I emerged in the presence of NVP (1 and 10
AM). Interestingly, clonal sequencing analysis of HIV-1
culture (NVP 1 AM) isolated from Case 23 revealed that
K102R and V106A always coexisted on the same molecules
and that V108I did not coexist with K102R and V106A
(Table 2). All clones analyzed had V35I, R83K, I135T,
T200K, R211K, and K238S. Four of these mutations (V35I,
R83K, I135T, and R211K) are known as polymorphic
mutations and were frequently observed in HIV-1 isolated
from treatment-naRve individuals in our cohort (72%, 18%,
27%, and 36%, respectively, n = 11). T200K and K238S had
not been reported previously and might be associated with
NVP resistance.
Phylogenetic analysis of clinical HIV-1 isolates
Because the clinical HIV-1 isolates derived from Cases
33 and 23 had unusually high resistance against NVP and
had exactly the same amino acid substitutions (V35I,
R83K, I135T, T200K, R211K, and K238S), we suspected
that these two patients had acquired HIV-1 infection from
a single infected patient. Then, we phylogenetically
analyzed the direct sequences of env region and RT gene
of the two HIV-1 isolates derived from Cases 33 and 23,
and then compared their sequences with four clinical
isolates derived from other patients (Cases 2, 3, 26, and
29) and five referential unrelated strains [U63632,
HXB2CG, OY1, RF, and simian immunodeficiency virus
(SIV)]. In both phylogenetic trees using the sequences of
the env region and RT gene, Cases 33- and 23-derived
sequences formed a tight cluster separated from other
sequences by the tree branch with high bootstrap proba-
bilities (99% and 100%) (Figs. 2A and B), suggesting that
the isolates from Cases 33 and 23 were genetically closely
related and probably originated from a single source. It
was noteworthy that the env sequences derived from Cases
33 and 23 were closely related but not identical, which
excludes the possibility of contamination during the
procedures of viral culture and PCR.
Three-dimensional positions of mutations and NVP-binding
pocket in HIV-1 RT
To delineate the positional relationship between NVP-
binding pocket and the mutations in RT described above, a
structural model of HIV-1 RT complexed with NVP was
Table 1
Results of phenotypic drug resistance testing in two untreated patients
HIV-1 IC50
a [AM] (fold resistanceb)
AZT 3TC d4T ABC NVP EFV
Case 33 0.04 F 0.03 (1.2) 0.61 F 0.20 (1.8) 1.7 F 0.10 (0.77) 3.6 F 0.87 (2.3) 2.2 F 0.29 (69) 0.011 F 0.003 (4.2)
Case 23 0.12 F 0.03 (3.5) 0.81 F 0.15 (2.4) 3.2 F 0.95 (1.5) 3.3 F 0.87 (2.1) N10 (N310) 0.023 F 0.00002 (8.8)
Data are mean F SD. Numbers in parentheses represent fold resistance.
a Phenotypic drug resistance assay was performed using MAGIC-5 cells.
b Fold resistance was calculated by dividing IC50 of clinical isolate by that of NL4-3 (AZT, 0.034 AM; 3TC, 0.34 AM; d4T, 2.2 AM; ABC, 1.6 AM; NVP,
0.032 AM; EFV, 0.0026 AM).
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(Ren et al., 2000). The Val residues at 106 and 108 codons
of RT (V106 and V108), the site of NNRTI resistance-
associated mutations, V106A and V108I, respectively, were
in close contact with NVP, packed in the hydrophobic
pocket of the palm domain. Five residues, V35, R83, I135,
T200, and R211, were located distantly from the hydro-
phobic pocket. Two residues, K102 and K238, were located
outside the frame of hydrophobic pocket and the substitu-
tions of these amino acids, such as K102R and K238S, were
thought to produce some structural changes of the pocket
and might be associated with NNRTI resistance.
Role of K102R and K238S in HIV-1 replication and
resistance against NVP
Because K238S has not been reported previously and
K102 and K238 were located on the frame of NVP-
binding pocket, we chose to construct seven recombinant
HIV-1 strains, HIV-1K102R, HIV-1V106A, HIV-1V108I, HIV-
1K238S, HIV-1V106A/K238S, HIV-1V108I/K238S, and HIV-
1K102R/V106A/K238S, to delineate the effects of K102R and
K238S on viral susceptibility against NVP. K102R did not
confer significant resistance against NVP and EFV (Table
3), while V106A and V108I, both of which were known as
NVP resistance-associated mutations, conferred 97- and
3.8-fold resistance against NVP, respectively. However,Table 2
Sequences of HIV-1 RT-coding region of clinical samples and isolates
Sequenced
sample
Amino acid residue
35 83 100a 102 103a 106a 1
HXBII V R L K K V V
Case 33 plasma I K – – – – –
1 AMb I K – – – – V
Case 23 plasma I K – K/R – – –
1 AMb I K – K/R – V/A V
10 AMb I K – K/R – A V
Number of clones
Isolate from
Case 23
(1 AMb)
15 I K – R – A –
3 I K – – – – –
2 I K – – – – I
1 I K – – R – –
Amino acids identical to HXBII (top column) are indicated with dashes.
a Reported residue associated with NVP resistance (Johnson et al., 2003).
b Cultured HIV-1 isolate in the presence of NVP at the indicated concentrations.these mutations did not confer significant resistance against
EFV. K238S conferred a significant resistance against NVP
as did V108I. Interestingly, the combination of V106A and
K238S (V106A/K238S) conferred surprisingly high-level
resistance (530-fold) against NVP, and the combination of
V108I and K238S (V108I/K238S) also conferred high
resistance (56-fold) only against NVP but not against EFV
(Table 3). Furthermore, the triple combination of K102R,
V106A, and K238S (K102R/V106A/K238S), which were
found in 15 of 21 clones derived from Case 23 (Table 2),
also conferred high resistance (340-fold) against NVP,
although its effect on viral resistance against EFV was not
significant (Table 3). These data suggest that K238S is
strongly associated with NVP resistance in the combina-
tion with V106A or V108I.
We next analyzed the effects of K102R and K238S on
viral replication kinetics in the absence or presence of
NVP. The addition of K238S to HIV-1WT (HIV-1K238S)
reduced the replication of HIV-1WT in the absence of NVP,
and the addition of V108I to HIV-1K238S (generating HIV-
1V108I/K238S) further reduced the viral replication (Fig. 4A).
On the other hand, in the presence of NVP (1 AM), K238S
made HIV-1 replication-competent (HIV-1WT could not
replicate), and HIV-1V108I/K238S had facilitated viral repli-
cation (Fig. 4B). The combination of V106A to K238S
(HIV-1V106A/K238S) severely compromised viral replication
and the addition of K102R (HIV-1K102R/V106A/K238S) did08a 135 181a 188a 190a 200 211 230a 238
I Y Y G T R M K
T – – – K K – S
/I T – – – K K – S
T – – – K K – S
/I T – – – K K – S
/I T – – – K K – S
T – – – K K – S
T – – – K K – S
T – – – K K – S
T – – – K K – S
Fig. 2. Phylogenetic analysis of env sequences (A) and RT genes (B) of six
clinical isolates and five referential strains. Bootstrap probabilities of
important tree branches are shown as percentages.
Table 3
Drug resistance of recombinant HIV-1s
Recombinant HIV-1 IC50
a [AM] (fold resistanceb)
NVP EFV
K102R 0.047 F 0.02 (1.5) 0.002 F 0.001 (0.77)
V106A 3.1 F 0.36 (97) 0.002 F 0.0003 (0.77)
V108I 0.12 F 0.03 (3.8) 0.001 F 0.0001 (0.38)
K238S 0.14 F 0.04 (4.4) 0.002 F 0.0003 (0.77)
V106A/K238S 17 F 4.6 (530) 0.004 F 0.001 (1.5)
V108I/K238S 1.8 F 0.66 (56) 0.001 F 0.0001 (0.38)
K102R/V106A/K238S 11 F 3.1 (340) 0.002 F 0.0001 (0.77)
Data are mean F SD. Numbers in parentheses represent fold resistance.
a Phenotypic drug resistance assay was performed using MAGIC-5 cells.
b Fold resistance was calculated by dividing IC50 of clinical isolate by that
of NL4-3 (NVP; 0.032 AM, EFV; 0.0026 AM).
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(Fig. 4C). In the presence of NVP (1 AM), the combination
of V106A and K238S (HIV-1V106A/K238S) rendered HIV-1Fig. 3. The structure of the HIV-1 RT complexed with NVP. A view of the RT
1FKP.pdb obtained from the Protein Data Bank (Ren et al., 2000). The fingers, pa
red, green, and yellow, respectively. The p51 subunit is colored white. Residues of
colored. The van der Waals volumes of side chain of V106 and V108 (white) arereplicable, and the addition of K102R to V106A/K238S
(HIV-1K102R/V106A/K238S) did not significantly alter the
replication (Fig. 4D). These data showed that V108I/
K238S and V106A/K238S can confer viral replicability in
the presence of NVP, although the role of K102R when
combined with V106A/K238S remained to be determined.
To further define the significance of each mutation,
the viral replicability was compared among molecular
infectious HIV-1 clones described above in the presence
and absence of NVP using competitive HIV-1 replica-
tion assay (CHRA) (Kosalaraksa et al., 1999). Two
infectious HIV-1 clones to be compared for their fitness
were mixed and used to infect H9 cells, and their
population changes through passages were determined
by the relative peak height on sequencing electrogram.
In the absence of NVP, HIV-1WT readily outgrew HIV-complexed with NVP, generated using SYBYL 6.7 and the coordinate set
lm, thumb, and connection subdomains of the p66 subunit are colored blue,
the p66 subunit are yellow-colored, while those of the p51 subunit are white-
shown to interact with NVP (orange).
Fig. 4. Replication kinetics of recombinant HIV-1s. Graphs A and B show replication kinetics of HIV-1WT (solid diamonds), HIV-1V108I (open squares),
HIV-1K238S (open diamonds), and HIV-1V108I/K238S (solid triangles) in the absence and presence of NVP (1 AM), respectively. Graphs C and D show
replication kinetics of HIV-1WT (solid diamonds), HIV-1K102R (solid squares), HIV-1V106A (open squares), HIV-1K238S (open diamonds), HIV-1V106A/K238S
(solid triangles), and HIV-1K102R/V106A/K238S (open triangles) in the absence and presence of NVP (1 AM), respectively. The results shown are representative
of three independent experiments.
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however, HIV-1K238S predominated over HIV-1WT (Fig.
5B), suggesting that K238S compromised the viral
replication in the absence of NVP but conferred
resistance against NVP. Next, we analyzed the effect
of V106A and V108I on HIV-1K238S replication. In
comparison between HIV-1K238S and HIV-1V106A/K238S,
HIV-1K238S predominated over HIV-1V106A/K238S in the
absence of NVP (Fig. 5C), but was outgrown by HIV-
1V106A/K238S in the presence of NVP (1 AM) (Fig. 5D).
In comparison between HIV-1K238S and HIV-1V108I/K238S,
HIV-1K238S predominated over HIV-1V108I/K238S in the
absence of NVP (Fig. 5E), but was outgrown by HIV-
1V108I/K238S in the presence of NVP (1 AM) (Fig. 5F).
Taken together, these data suggest that each of V106A
and V108I compromised the viral replication in the
absence of NVP but conferred resistance against NVP.
Finally, we analyzed the effect of K102R on replication
of HIV-1WT and HIV-1V106A/K238S. HIV-1K102R was
slowly overcome by HIV-1WT in the absence of NVP
(Fig. 5G). In comparison between HIV-1V106A/K238S and
HIV-1K102R/V106A/K238S, HIV-1K102R/V106A/K238S predomi-
nated over HIV-1V106A/K238S both in the absence (Fig.
5H) and presence (1 AM) (Fig. 5I) of NVP. Considered
together, these results suggest that K102R compromised
the replication of HIV-1WT but compensated thereplication ability of HIV-1V106A/K238S regardless of the
presence of NVP.Discussion
Several studies reported the recent spread of drug-
resistant HIV-1 in the developed countries and among
treatment-naRve individuals as well, which has been a
menace for clinicians. Therefore, for certain treatment-naRve
patients, such as cases of acute or recent HIV-1 infection,
drug-resistance assay is recommended (Hirsch et al., 2003).
However, resistant HIV-1 can be replaced with wild-type
HIV-1 rapidly in plasma in the absence of treatment, and it
may be difficult to detect resistant HIV-1 in the treatment-
naRve patients even if they harbored resistant HIV-1. In this
regard, phenotypic assay may be superior to genotypic assay
using direct sequencing, because in phenotypic assay,
resistant viruses could be propagated during culture in the
presence of antiretroviral agents, while direct sequencing
can only detect relatively major viral population in plasma.
In fact, in the present study, the phenotypic assay using
MAGIC-5 cells detected two highly NVP-resistant isolates
in treatment-naRve patients, in whom direct sequencing
failed to detect the presence of minor population of V106A
and V108I.
Fig. 5. Competitive HIV-1 replication assay for recombinant HIV-1s. Two infectious HIV-1 clones to be compared for their fitness were mixed and used to
infect H9 cells in the absence (A, C, E, G, and H) and presence of NVP (B: 0.1 AM; D, F, and I: 1 AM). The cell-free supernatant was transferred to fresh H9
cells every 7 days. High-molecular-weight DNAs extracted from infected cells at the end of each passage were subjected to nucleotide sequencing, and
proportion of Lys and Ser at position 238 (Graphs A and B), those of Val and Ala at position 106 (Graphs C and D), those of Val and Ile at position 108 (Graphs
E and F), and those of Lys and Arg at position 102 (Graphs G–I) were determined.
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because a single formulation of NVP combined with d4T
and 3TC is a generic drug widely used in resource-limited
situations (Cohen, 2003; Penzak et al., 2003). The use of
NVP in pregnant women is also one of the main strategies to
prevent mother-to-child transmission of HIV-1 (Guay et al.,
1999; Marseille et al., 1999). Therefore, understanding of themechanism of NVP resistance development is urgently
needed.
In the present study, we identified a novel mutation,
K238S, which was associated with a high multitude of NVP
resistance when it was coupled with V106A or V108I.
Interestingly, direct sequencing identified only K238S in the
two patients infected with highly NVP-resistant HIV-1.
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to their wild-type V106 and V108, respectively, in major
viral populations in the plasma. Furthermore, the results
indicate that K238S can remain longer than V106A and
V108I in the absence of NVP treatment, partly because at
least two nucleotide substitutions are required for K238S
while V106A and V108I can occur with only a single
nucleotide substitution.
M230 is located on the opposite side of Q151 in relation
to the incoming dNTP, forming the primer grip of RT and
contacting the primer strand (Huang et al., 1998; Sarafianos
et al., 1999), and several mutations around this site were
reported to occur in patients during NNRTI treatment.
Parkin et al. (2000) observed the emergence of F227L and
M230L during NVP-containing combination therapy and it
was associated with the loss of NVP susceptibility of their
clinical isolates. Demeter et al. (2000) reported that P236L
occurred in subjects receiving delavirdine monotherapy.
With regard to K238, Demeter et al. (1998) observed the
emergence of K238T in one patient treated with atevirdine
(an NNRTI) and AZT. Considering these reports, the region
containing M230 and K238 is important for drug suscept-
ibility and there may be more resistance-associated muta-
tions around these sites.
Phylogenetic analysis showed a close relation between
the isolates from Cases 33 and 23 (Fig. 2), suggesting that
the two patients had acquired HIV-1 infection from the same
source, although they did not know each other and
interviewing them could not identify the source patient.
This source patient presumably had been under antiretro-
viral treatment including NVP, which had failed to suppress
his viral load because of the sets of mutations, K102R/
V106A/K238S and V108I/K238S. It remains unknown
whether K238S had existed as a polymorphism before the
introduction of antiretroviral treatment, or it had emerged
during NVP treatment in the source patient. Considering
that a single dose of NVP to prevent mother-to-child
transmission can induce resistant strains (Morris et al.,
2003; Sullivan, 2003), some polymorphic mutations in
treatment-naRve population could be associated with NVP
resistance.Materials and methods
Reagents and cells
AZT, d4T, and ABC were purchased from Sigma Co.
(Tokyo, Japan). 3TC, NVP, and EFV were generously
provided by Nippon Glaxo-Smithkline (Tokyo, Japan),
Boehringer Ingelheim Pharmaceutics Inc. (Ridgefield,
CT), and Merck Co. Inc. (Rahway, NJ), respectively.
H9 cells and COS-7 cells were grown in RPMI 1640 and
Dulbecco’s modified eagle medium (DMEM), respectively,
supplemented with 10% fetal calf serum (FCS), penicillin
(100 U/ml), and streptomycin (100 Ag/ml). MAGIC-5 cells(CCR5 and CD4 expressing HeLa-LTR-h-gal cells)
(Hachiya et al., 2001, 2003) were grown in DMEM
supplemented with 10% FCS, hygromycin B (100 Ag/ml)
(Invitrogen Co., Carlsbad, CA), and blasticidin (1 Ag/ml)
(Funakoshi, Tokyo). Peripheral blood mononuclear cells
(PBMCs) obtained from healthy donors were stimulated by
phytohemagglutinin (PHA) in RPMI 1640-based medium
containing interleukin-2 (20 U/ml) (R & D Systems,
Minneapolis, MN) for 2 days before HIV-1 exposure.
Patients and clinical isolates
Clinical strains were isolated from fresh plasma of the
study participants attending the outpatient clinic of the
AIDS Clinical Center, International Medical Center of
Japan, by using MAGIC-5 cells as described previously
(Hachiya et al., 2001). The obtained isolates were stored at
80 8C until use and the infectivity was measured as blue
cell-forming unit (BFU) of MAGIC-5 cells (Hachiya et al.,
2001). The Institutional Review Board approved this study
(IMCJ-H13-80) and a written informed consent was
obtained from all the participants.
Case 33 was a 33-year-old homosexual man. He suffered
from high fever and severe headache, probably symptoms of
primary HIV-1 infection, in April 2000. On May 15,
Western blotting showed faint bands against HIV-1 gp160,
p68, p55, p25, and p18 antigens. One week after, these
bands became bold and new bands against HIV-1 gp110,
p40, and p34 antigens appeared. The CD4 count was 401/Al
and HIV-1 viral load was 2.0  105/ml.
Case 23 was a 23-year-old homosexual man. He also
suffered from severe headache and was hospitalized in
January, 2001. Western blotting showed one faint band
against HIV-1 gp160 antigen. In April, 2001, the band
became bold and new bands against gp110, p68, p55, p52,
gp41, p40, p34, p25, and p18 antigens appeared. The CD4
count was 210/Al and HIV-1 viral load was 7.1  104/ml.
Sequence analyses of HIV-1 RT and V3 region
Viral RNA was extracted from plasma and clinical
isolates with Smi-test nucleic acid extraction kit (Genome
Science, Fukushima, Japan). The HIV-1 RT gene was
amplified by RT-PCR using One Step RNA PCR Kit
(Takara Shuzo, Otsu, Japan). For plasma-derived RNA,
nested PCR was conducted subsequently to amplify
enough DNA for direct sequencing. The sequences of
primer sets for the first PCR (T1 and T4) and the second
PCR (T12 and T15) were as follows (Gatanaga et al.,
1999; Hachiya et al., 2001, 2003): T1, 5V-AGGGG-
GAATTGGAGGTTT (RF positions, 1910 to 1927); T4,
5V-TTCTGTTAGTGCTTTGGTT (RF positions, 2939–
2921); T12, 5V-CCAGTAAAATTAAAGCCAG (RF posi-
tions, 2091–2109); and T15, 5V-TCCCACTAACTTCTG-
TATGTC (RF positions, 2852–2832). The gp120 V3
domain of several HIV-1 isolates was amplified by RT-
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first PCR (ES1 and EA1) and the second PCR (ES2 and
EA2) were as follows (Ida et al., 1997): ES1, 5V-
AATGTCAGCACAGTACAATGTACAC (RF positions,
6502–6526); EA1, 5V-ACAATTTCTGGGTCCCCTCCT-
GAGGA (RF positions, 6890–6865); ES2, 5V-ATGGAAT-
TAGGCCAGTAGTG (RF positions, 6527–6546); EA2,
5V-CTCCTAATTTTGTAACTAC (RF positions, 6829–
6811). Specific precautions, including physical separation
of processing areas, were taken to avoid template and
amplified product carryover. Stringent quality control to
prevent PCR contamination was employed to protect
against cross-contamination of product DNA. Direct
sequencing was performed using dye terminators (BigDye
Terminator Cycle Sequencing Ready Reaction Kit; Applied
Biosystems, Foster, CA) and model 3700 automated DNA
sequencer (Applied Biosystems). Amino acid sequences
were deduced with the Genetyx-Win program version 4.1
(Software Development, Tokyo). For some PCR products,
molecular cloning was performed with pT7 Blue T-Vector
(Novagen, CA) and their sequences were analyzed.
For the phylogenetic analysis, RT gene and V3 sequences
were aligned by Clustal-W programwith reference sequences
from the Los Alamos sequence database. The results of the
alignment were then analyzed by the neighbor-joining
method and the distance matrixes were generated with
Kimura two-parameter model.
Bootstrap resampling (1000 data sets) of the multiple
alignments was performed to test the statistical robustness of
the tree.
Construction of recombinant HIV-1 clones
Recombinant infectious HIV-1 clones carrying various
mutations in RT were constructed with a site-directed
mutagenesis. Briefly, the desired mutations were introduced
into XmaI–NheI region (759 bp) of pTZNX1, which encoded
Gly-15 to Ala-267 of HIV-1 RT (strain BH 10), by the
oligonucleotide-based mutagenesis method (Kodama et al.,
2001). The XmaI–NheI fragment was inserted into pNL101-
based plasmid (a kind gift from Jeang Kuan-The, NIAID/
NIH, Bethesda, MD), generating various molecular clones
with the desired mutations. Determination of the nucleotide
sequences of plasmids confirmed that each clone had the
desired mutations but no unintended mutations. Each
molecular clone (10 Ag/ml as DNA) was transfected into
COS-7 cells (4  105 cells/100-mm-diameter dish) by
Fugene transfection reagent (Roche Diagnosis, Basal, Swit-
zerland). After 48 h, culture supernatants were harvested and
stored at 80 8C until use. The infectivity of the viruses was
determined as BFU in MAGIC-5 cells.
Drug susceptibility assay with MAGIC-5 cells
HIV-1 drug susceptibility to various RTIs was determined
in triplicate by using MAGIC-5 cells as described previously(Hachiya et al., 2001). Briefly, MAGIC-5 cells were infected
with adjusted virus stock (300 BFU) in the presence of
increasing concentrations of RTIs, cultured for 48 h, fixed,
and stained with 5-bromo-4-chloro-3-indolyl-h-d-galacto-
pyranoside (Takara Shuzo). The blue-stained cells were
counted under a light microscope. Drug concentrations that
inhibited 50% of the stained cells of drug-free control (IC50)
were determined by referring to the dose–response curve.
Viral replication kinetic assays
PHA-stimulated PBMCs were exposed to each infec-
tious virus preparation (300 BFU) in a final volume of
200 Al for 2 h. Infected cells were then washed and
cultured in a volume of 200 Al in the absence or
presence of NVP (1 AM). Assays were performed in
triplicate and repeated at least three times using inde-
pendently generated virus preparations. On days 0, 2, 4,
6, and 8 of infection, 100-Al aliquots of culture super-
natants were filtered and stocked for measurements of
p24 antigen concentration and replaced with equal
amount of fresh medium with or without NVP. The
concentrations of p24 in the supernatants were deter-
mined by chemiluminescence enzyme immunoassay
(CLEIA) kit (Fuji-Rebio, Tokyo, Japan).
Competitive HIV-1 replication assay
Freshly prepared H9 cells (3  105) were exposed to
virus preparations (300 BFU) to be examined for their
replication ability and cultured in the presence or absence
of NVP as described previously (Gatanaga et al., 2002;
Kosalaraksa et al., 1999; Yoshimura et al., 1999). On day
1 in culture, one-third of the infected H9 cells were
harvested and washed twice with PBS, and cellular DNA
was extracted with Smi-test nucleic acid extraction kit.
Purified DNAs were subjected to nested PCR for
sequencing HIV-1 RT gene. Every 7 days, the super-
natant of the virus culture was transmitted to new
uninfected H9 cells, the cells harvested at each passage
were subjected to direct DNA sequencing of HIV-1 RT
gene, and the viral population change was determined by
the relative peak height on sequencing electrogram. The
persistence of the original amino acid substitution was
confirmed for all infectious clones used in this assay.
Structural analysis of mutations in HIV-1 RT
To examine the interaction of HIV-1 RT with NVP, the
SYBYL 6.7 (http://www.tripos.com/, Tripos Associates,
St. Louis, MO) on a Silicon Graphics Octane2 work-
station was employed. The site of the enzyme ligand
complex was constructed based on the previously
reported X-ray structure of the covalently trapped
catalytic complex of HIV-1 RT with NVP (Protein Data
Bank entry 1FKP) (Ren et al., 2000).
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